A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults

NCT02030457 ↗

Phase 1 Completed 72 enrolled Teva Branded Pharmaceutical Products R&D, Inc.

RandomizedCrossoverOpen-labelOther

Summary

This study is designed to compare the systemic exposure of orally inhaled beclomethasone dipropionate inhalation aerosol delivered via BAI to that delivered via MDI.

Timeline

Start: 2013-12
Primary completion: 2014-04
Completion: 2014-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	beclomethasone dipropionate	Other / unclassified	160 ug	Inhaled
Subject	beclomethasone dipropionate	Other / unclassified	320 ug	Inhaled

Indications

No indication recorded.